Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : Poxel
Deal Size : Undisclosed
Deal Type : Termination
Poxel Regains Imeglimin Rights From Metavant
Details : Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 14, 2021
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : Poxel
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Sumitomo Pharma Oncology
Deal Size : Not Applicable
Deal Type : Not Applicable
Poxel Provides Update on Metavant Partnership with Imeglimin
Details : Metavant has conducted a strategic review and has decided not to move forward with the development of Imeglimin. Metavant will actively explore options for a potential out-licensing of Imeglimin rights for a period of 60 day.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2020
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Sumitomo Pharma Oncology
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
